IP Library › Granted Patent US 12,553,024
Granted Patent B2
US 12,553,024 · App. 16/770,052 · Granted Feb 17, 2026

Serum-free media formulation for culturing cells and methods of use thereof

Inventors: Pascal Beauchesne (Seattle, WA); Kien Khuu-Duong (Seattle, WA); Ivie Aifuwa (Seattle, WA); Calvin Chan (Seattle, WA)
Assignee: Juno Therapeutics, Inc.
C12N5/0031A61K40/11A61K40/31A61K40/4215C12N5/0636A61K2239/31A61K2239/38A61K2239/48C12N2500/32C12N2500/90C12N2501/2302C12N2501/2307C12N2501/2315C12N2501/515C12N2510/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,553,024
App. No.
16/770,052
Granted
Feb 17, 2026
Kind
B2
Abstract

Provided herein is a serum-free media for culturing, such as cultivating, preparing and/or producing cells, such as immune cells, such as genetically engineered cells. Also provided is a liquid basal media and frozen supplements that can be used to produce serum-free media. The provided embodiments include methods for producing serum-free media and methods for culturing cells, such as activating, transducing, cultivating or expanded cells, in the presence of serum-free media.

Claims (30)

1 . A serum-free medium for use for culturing T cells, comprising:

(a) 1 mM to 3 mM of L-alanyl-L-glutamine;

(b) 1 mM to 3 mM of L-glutamine;

(c) 100 IU/mL to 200 IU/mL of IL-2;

(d) 500 IU/mL to 1400 IU/mL of IL-7;

(e) 100 IU/mL to 200 IU/mL of IL-15;

(f) at least one protein, wherein the at least one protein comprises human serum albumin; and

(g) a base medium;

wherein the serum-free medium is free of serum.

2 . The serum-free medium of claim 1 , wherein:

the concentration of IL-2 in the serum free medium is 100 IU/mL or 200 IU/mL;

the concentration of IL-7 in the serum free medium is 600 IU/mL or 1,200 IU/mL; and

the concentration of IL-15 in the serum free medium is 100 IU/mL or 200 IU/mL.

3 . The serum-free medium of claim 1 , wherein:

the concentration of IL-2 in the serum free medium is 100 IU/mL;

the concentration of IL-7 in the serum free medium is 600 IU/mL; and

the concentration of IL-15 in the serum free medium is 100 IU/mL.

4 . The serum-free medium of claim 1 , wherein:

the concentration of IL-2 in the serum free medium is 200 IU/mL;

the concentration of IL-7 in the serum free medium is 1,200 IU/mL; and

the concentration of IL-15 in the serum free medium is 200 IU/mL.

5 . The serum-free medium of claim 1 , wherein the at least one protein comprises human serum albumin and one or both of transferrin and insulin.

6 . The serum-free medium of claim 1 , wherein the concentration of the L-alanyl-L-glutamine in the serum-free medium is from 1.5 mM to 2.5 mM.

7 . The serum-free medium of claim 1 , wherein the concentration of the L-glutamine in the serum-free medium is from 1.5 mM to 2.5 mM.

8 . The serum-free medium of claim 1 , wherein the concentration of the L-alanyl-L-glutamine in the serum-free medium is from 1.5 mM to 2.5 mM, and the concentration of the L-glutamine in the serum-free medium is from 1.5 mM to 2.5 mM.

9 . The serum-free medium of claim 1 , wherein the base medium comprises Dulbecco's Modified Eagle's Medium (DMEM), Minimal Essential Medium (MEM), Basal Medium Eagle (BME), F-10, F-12, RPMI 1640, Glasgow's Minimal Essential Medium (GMEM), alpha Minimal Essential Medium (alpha MEM), Iscove's Modified Dulbecco's Medium, or M199.

10 . The serum-free medium of claim 1 , wherein the serum-free medium comprises 500 IU/mL to 1400 IU/mL of IL-7.

11 . The serum-free medium of claim 1 , wherein the serum-free medium comprises 100 IU/mL to 200 IU/mL of IL-15.

12 . The serum-free medium of claim 1 , wherein serum-free medium does not comprise phenol red.

13 . The serum-free medium of claim 8 , wherein the serum-free medium does not comprise phenol red.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 30, 2021
From: BEAUCHESNE, PASCAL; KHUU-DUONG, KIEN; AIFUWA, IVIE; CHAN, CALVIN
To: JUNO THERAPEUTICS, INC.
Reel/Frame 057318/0084 →
Continuity (2)
Provisional Application 62596766 · Dec 8, 2017
Related Publication 20210207080A1 · Jul 8, 2021
References Cited (319)
US 4452773A · Molday · 1984 [cited by applicant]
US 4690915A · Rosenberg · 1987 [cited by applicant]
US 4795698A · Owen · 1989 [cited by applicant]
US 5087616A · Myers · 1992 [cited by applicant]
US 5168062A · Stinski · 1992 [cited by applicant]
US 5200084A · Liberti · 1993 [cited by applicant]
US 5219740A · Miller · 1993 [cited by applicant]
US 5385839A · Stinski · 1995 [cited by applicant]
US 5994136A · Naldini et al. · 1999 [cited by applicant]
US 6013516A · Verma et al. · 2000 [cited by applicant]
US 6040177A · Riddell et al. · 2000 [cited by applicant]
US 6060273A · Dirks et al. · 2000 [cited by applicant]
US 6123655A · Fell · 2000 [cited by applicant]
US 6207453B1 · Maass · 2001 [cited by applicant]
US 6410319B1 · Raubitschek · 2002 [cited by applicant]
US 6451995B1 · Cheung · 2002 [cited by applicant]
US 6733433B1 · Fell · 2004 [cited by applicant]
US 7070995B2 · Jensen · 2006 [cited by applicant]
US 7265209B2 · Jensen · 2007 [cited by applicant]
US 7354762B2 · Jensen · 2008 [cited by applicant]
US 7446179B2 · Jensen · 2008 [cited by applicant]
US 7446190B2 · Sadelain · 2008 [cited by applicant]
US 7446191B2 · Jensen · 2008 [cited by applicant]
US 8008450B2 · Williams et al. · 2011 [cited by applicant]
US 8153765B2 · Park et al. · 2012 [cited by applicant]
US 8324353B2 · Jensen · 2012 [cited by applicant]
US 8339645B2 · Nakawaki · 2012 [cited by applicant]
US 8389282B2 · Sadelain et al. · 2013 [cited by applicant]
US 8479118B2 · Lyndersay et al. · 2013 [cited by applicant]
US 8603477B2 · Afar et al. · 2013 [cited by applicant]
US 8802374B2 · Jensen · 2014 [cited by applicant]
US 8822647B2 · Jensen · 2014 [cited by applicant]
US 8911993B2 · June et al. · 2014 [cited by applicant]
US 10131882B2 · Angel et al. · 2018 [cited by applicant]
US 10428351B2 · Crisman et al. · 2019 [cited by applicant]
US 11466253B2 · Germeroth et al. · 2022 [cited by applicant]
US 11851678B2 · Mujacic et al. · 2023 [cited by applicant]
US 12258580B2 · Lee et al. · 2025 [cited by applicant]
US 20020131960A1 · Sadelain · 2002 [cited by applicant]
US 20020150914A1 · Anderse et al. · 2002 [cited by applicant]
US 20030170238A1 · Gruenberg et al. · 2003 [cited by applicant]
US 20030223994A1 · Hoogenboom et al. · 2003 [cited by applicant]
US 20040191260A1 · Reiter et al. · 2004 [cited by applicant]
US 20060034850A1 · Weidanz et al. · 2006 [cited by applicant]
US 20070092530A1 · Weidanz et al. · 2007 [cited by applicant]
US 20070116690A1 · Yang et al. · 2007 [cited by applicant]
US 20080171951A1 · Fell · 2008 [cited by applicant]
US 20090226474A1 · Weidanz et al. · 2009 [cited by applicant]
US 20090233360A1 · Baghbaderani et al. · 2009 [cited by applicant]
US 20090304679A1 · Weidanz · 2009 [cited by applicant]
US 20100260748A1 · Elkins et al. · 2010 [cited by applicant]
US 20110003380A1 · Miltenyi · 2011 [cited by applicant]
US 20110293667A1 · Baksh et al. · 2011 [cited by applicant]
US 20120189622A1 · Tesar et al. · 2012 [cited by applicant]
US 20130029418A1 · Angel et al. · 2013 [cited by applicant]
US 20130149337A1 · Cooper et al. · 2013 [cited by applicant]
US 20130287748A1 · June · 2013 [cited by applicant]
US 20140255993A1 · Follstad et al. · 2014 [cited by applicant]
US 20140271635A1 · Brogdon et al. · 2014 [cited by applicant]
US 20140294841A1 · Scheinberg et al. · 2014 [cited by applicant]
US 20150283178A1 · June et al. · 2015 [cited by applicant]
US 20160152723A1 · Chen et al. · 2016 [cited by applicant]
US 20160362472A1 · Bitter et al. · 2016 [cited by applicant]
US 20170037369A1 · Ramsborg et al. · 2017 [cited by applicant]
US 20170051252A1 · Morgan et al. · 2017 [cited by applicant]
US 20170209492A1 · June et al. · 2017 [cited by applicant]
US 20200239910A1 · Bonyhadi · 2020 [cited by applicant]
US 20200354677A1 · Lee et al. · 2020 [cited by applicant]
US 20200384025A1 · Mujacic et al. · 2020 [cited by applicant]
US 20210017249A1 · Sather et al. · 2021 [cited by applicant]
US 20210163893A1 · Westoby et al. · 2021 [cited by applicant]
US 20230090117A1 · Haig et al. · 2023 [cited by applicant]
US 20240076617A1 · Mujacic et al. · 2024 [cited by applicant]
US 20250171739A1 · Lee et al. · 2025 [cited by applicant]
CN 104450614A · 2015 [cited by applicant]
CN 106635955A · 2017 [cited by applicant]
CN 106754670A · 2017 [cited by applicant]
CN 106801032 · 2017 [cited by applicant]
CN 106834218 · 2017 [cited by applicant]
EP 0452342 · 1991 [cited by applicant]
EP 2537416 · 2012 [cited by applicant]
EP 3372670 · 2018 [cited by applicant]
WO WO1992008796 · 1992 [cited by applicant]
WO WO1994028143 · 1994 [cited by applicant]
WO WO1996013593 · 1996 [cited by applicant]
WO WO1996018105 · 1996 [cited by applicant]
WO WO1999018129 · 1999 [cited by applicant]
WO WO1999060120 · 1999 [cited by applicant]
WO WO2000014257 · 2000 [cited by applicant]
WO WO2000038762 · 2000 [cited by applicant]
WO WO2003020763 · 2003 [cited by applicant]
WO WO2003068201 · 2003 [cited by applicant]
WO WO2004033685 · 2004 [cited by applicant]
WO WO2006000830 · 2006 [cited by applicant]
WO WO2006099875 · 2006 [cited by applicant]
WO WO2008035631 · 2008 [cited by applicant]
WO WO2009072003 · 2009 [cited by applicant]
WO WO2009076524 · 2009 [cited by applicant]
WO WO2009080829 · 2009 [cited by applicant]
WO WO2010033140 · 2010 [cited by applicant]
WO WO2010104949 · 2010 [cited by applicant]
WO WO2011044186 · 2011 [cited by applicant]
WO WO2012081650 · 2012 [cited by applicant]
WO WO2012092612 · 2012 [cited by applicant]
WO WO2012129514 · 2012 [cited by applicant]
WO WO2013071154 · 2013 [cited by applicant]
WO WO2013123061 · 2013 [cited by applicant]
WO WO2013126726 · 2013 [cited by applicant]
WO WO2013163171 · 2013 [cited by applicant]
WO WO2013166321 · 2013 [cited by applicant]
WO WO2014031687 · 2014 [cited by applicant]
WO WO2014055668 · 2014 [cited by applicant]
WO WO2014210064 · 2014 [cited by applicant]
WO WO2015095895 · 2015 [cited by applicant]
WO WO2015157252 · 2015 [cited by applicant]
WO WO2015157384 · 2015 [cited by applicant]
WO WO2015158868 · 2015 [cited by applicant]
WO WO2015164675 · 2015 [cited by applicant]
WO WO2015164745 · 2015 [cited by applicant]
WO WO2015181253 · 2015 [cited by applicant]
WO WO2016019300 · 2016 [cited by applicant]
WO WO2016073602 · 2016 [cited by applicant]
WO WO2016090190 · 2016 [cited by applicant]
WO WO2016090312 · 2016 [cited by applicant]
WO WO2016090320 · 2016 [cited by applicant]
WO WO2016090327 · 2016 [cited by applicant]
WO WO2016090329 · 2016 [cited by applicant]
WO WO2016090369 · 2016 [cited by applicant]
WO WO2016109410 · 2016 [cited by applicant]
WO WO2016164580 · 2016 [cited by applicant]
WO WO2016164731 · 2016 [cited by applicant]
WO WO2017015427 · 2017 [cited by applicant]
WO WO2017015490 · 2017 [cited by applicant]
WO WO2017023803 · 2017 [cited by applicant]
WO WO2017027291 · 2017 [cited by applicant]
WO WO2017068421 · 2017 [cited by applicant]
WO WO2017070337 · 2017 [cited by applicant]
WO WO2017096329 · 2017 [cited by applicant]
WO WO2017156479 · 2017 [cited by applicant]
WO WO2017157505 · 2017 [cited by applicant]
WO WO2017161353 · 2017 [cited by applicant]
WO WO2017173256 · 2017 [cited by applicant]
WO WO2017177137 · 2017 [cited by applicant]
WO WO2018106732 · 2018 [cited by applicant]
WO WO2018162352 · 2018 [cited by applicant]
WO WO2018191723 · 2018 [cited by applicant]
WO WO2019089855 · 2019 [cited by applicant]
WO WO2019113556 · 2019 [cited by applicant]
WO WO2019113557 · 2019 [cited by applicant]
WO WO2020033927 · 2020 [cited by applicant]
US 8,252,592 B2, 08/2012, Sadelain (withdrawn) [cited by applicant]
EX-CELL 302. Material Safety Data Sheet. SAFC Bioscience. p. 1-2. (Year: 2006). [cited by examiner]
Technical Bulletin. Animal-Component Free Recombinant Human Insulin is Suitable for Use in Serum-Free Media. SAFC Bioscience. p. 1-4 (Year: 2006). [cited by examiner]
Karnieli et al. A consensus introduction to serum replacements and serum-free media for cellular therapies. Cytotherapy, 2017; 19: 155-169 (Year: 2017). [cited by examiner]
Jeon et al. Development of a serum-free medium for in vitro expansion of human cytotoxic T lymphocytes using a statistical design. BMC Biotechnology Oct. 2010:70. p. 1-9 (Year: 2010). [cited by examiner]
GlutaMAX-1. Gibco. p. 1 (Year: 2010). [cited by examiner]
RPMI-1640 medium. Sigma-Aldrich. p. 1-2 (Year: 2007). [cited by examiner]
WHO unit chart. PeproTech. downloaded from https://www.peprotech.com/en/who-unit-chart. p. 1-2 (Year: 2023). [cited by examiner]
RPMI 1640. catalog #32404, downloaded from https://www.thermofisher.com/us/en/home/technical-resources/media-formulation.192.html. p.1-2 (Year: 2023). [cited by examiner]
Litvinova et al. The Influence of Immunoregulatory Cytokines IL-2, IL-7, and IL-15 upon Activation, Proliferation, and Apoptosis of Immune Memory T-cells in vitro Cell and Tissue Biology, 2013, vol. 7, No. 6, pp. 539-54… [cited by examiner]
Al-Lazikani et al., “Standard conformations for the canonical structures of immunoglobulins,” J Mol Biol (1997) 273(4):927-948. [cited by applicant]
Alonso-Camino et al., “CARbodies: Human Antibodies Against Cell Surface Tumor Antigens Selected From Repertoires Displayed on T Cell Chimeric Antigen Receptors,” Mol Ther Nucl Acids (2013) 2: e93. [cited by applicant]
Barrett et al., “Chimeric Antigen Receptor Therapy for Cancer,” Annu Rev Med (2014) 65:333-347. [cited by applicant]
Baum et al., “Retrovirus Vectors: Toward the plentivirus,” Mol Ther (2006) 13:1050-1063. [cited by applicant]
Benson et al., “CS1-Directed monoclonal antibody therapy for multiple myeloma,” J Clin Oncol (2012) 30(16):2012-2015. [cited by applicant]
Boris-Lawrie et al., “Recent advances in retrovirus vector technology,” Cur. Opin. Genet. Develop. (1993) 3:102-109. [cited by applicant]
Brash et al., “Strontium phosphate transfection of human cells in primary culture: stable expression of the simian virus 40 large-T-antigen gene in primary human bronchial epithelial cells,” Mol. Cell Biol. (1987) 7: 20… [cited by applicant]
Brentjens et al., “CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia,” Sci Transl Med. (2013) 5(177):177ra38. [cited by applicant]
Brown et al., “Structure-Based Mutagenesis of the Human Immunodeficiency Virus Type 1 DNA Attachment Site: Effects on Integration and cDNA Synthesis,” J Viral (1999) 73(11):9011-9020. [cited by applicant]
Burns et al., “Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells,” Proc. Natl. Acad. Sci. USA (1… [cited by applicant]
Carlens et al., “Ex vivo T lymphocyte expansion for retroviral transduction: influence of serum-free media on variations in cell expansion rates and lymphocyte subset distribution,” Exp Hematol (2000) 28(10): 1137-1146. [cited by applicant]
Carpenter et al., “B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma,” Clin Cancer Res. (2013) 19:2048-2060. [cited by applicant]
Cavalieri et al., “Human T lymphocytes transduced by lentiviral vectors in the absence of TCR activation maintain an intact immune competence,” Blood (2003) 102(2): 497-505. [cited by applicant]
Cheadle et al., “Chimeric antigen receptors for T-cell based therapy,” Methods Mol Biol (2012) 907:645-666. [cited by applicant]
Cheever et al., “The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research.” Clin Cancer Res. Sep. 1, 2009;15(17):5323-37. [cited by applicant]
Chervin et al., “Engineering higher affinity T cell receptors using a T cell display system,” J Immunol Methods. (2008) 339(2): 175-84. [cited by applicant]
Chicaybam et al., “An efficient low cost method for gene transfer to T lymphocytes,” PLoS One (2013) 8(3): e60298. [cited by applicant]
Cho et al., “Human mammalian cell sorting using a highly integrated micro-fabricated fluorescence-activated cell sorter (μFACS),” Lab on a Chip (2010) 10:1567-1573. [cited by applicant]
Chothia et al.,. “The outline structure of the T-cell alpha beta receptor,” EMBO J. (1988) 7(12): 3745-55. [cited by applicant]
Chu et al., “CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma,” Leukemia (2014) 28(4):917-927. [cited by applicant]
Clackson et al., “Making antibody fragments using phage display libraries,” Nature (1991) 352(6336):624-628. [cited by applicant]
Cohen et al., “Recognition of Fresh Human Tumor by Human Peripheral Blood Lymphocytes Transduced with a Bicistronic Retroviral Vector Encoding a Murine Anti-p53 TCR,” J Immunol (2005) 175(9):5799-5808. [cited by applicant]
Cohen et al., “Recombinant antibodies with MHC-restricted, peptide-specific, T-cell receptor-like specificity: new tools to study antigen presentation and TCR—peptide—MHC interactions,” J Mol RecogN (2003) 16:324-332. [cited by applicant]
Cooper et al., “T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect,” Blood. (2003) 101:1637-1644. [cited by applicant]
Davila et al., “CD19 CAR-targeted T cells induce long-term remission and B Cell Aplasia in an immunocompetent mouse model of B cell acute lymphoblastic leukemia,” PLoS One (2013) 8(4): e61338. [cited by applicant]
De Felipe et al., “Targeting of proteins derived from self-processing polyproteins containing multiple signal sequences,” Trafic (2004) 5(8):616-626. [cited by applicant]
De Felipe, “Skipping the co-expression problem: the new 2A “Chysel” technology,” Genetics Vaccines and Therapy (2004) 2:13. [cited by applicant]
Dull, T. et al. (Nov. 1998) “A Third-Generation Lentivirus Vector with a Conditional Packaging System,” J. Viral. 72:8463-8471. [cited by applicant]
Engelman et al., “Multiple effects of mutations in human immunodeficiency virus type 1 integrase on viral replication,” J Viral (1995) 69(5):2729-2736. [cited by applicant]
Fedorov et al., “PD-1- and CTLA-4-Based Inhibitory Chimeric Antigen Receptors (iCARs) Divert Off-Target Immunotherapy Responses,” Sci Transl Medicine (2013) 5(215):215ra172. [cited by applicant]
Frecha et al., “Advances in the field of lentivector-based transduction of T and B lymphocytes for gene therapy,” Mol Ther (2010) 18(10):1748-1757. [cited by applicant]
Garfall et al., “Immunotherapy with chimeric antigen receptors for multiple myeloma,” Discov Med (2014) 17(91):37-46. [cited by applicant]
Garfall et al., “Posterior Reversible Encephalopathy Syndrome (PRES) after infusion of anti-Bcma CAR T cells (CART_BCMA) for multiple myeloma: Successful Treatment with Cyclophophamide,” Blood (2016) 128(22):5702. [cited by applicant]
Gargett et al., “Different cytokine and stimulation conditions influence the expansion and immune phenotype of third-generation chimeric antigen receptor T cells specific for tumor antigen GD2,” Cytotherapy (2015) 17(4)… [cited by applicant]
Gibco, CTS™ Immune Cell SR (2015). [cited by applicant]
Gibco, OpTmizer™ T-cell Expansion SFM (2008). [cited by applicant]
Godin et al., “Microfluidics and photonics for Bio-System-on-a-Chip: A review of advancements in technology towards a microfluidic flow cytometry chip,” J Biophotonics (2008) 1(5):355-376. [cited by applicant]
Hackett et al., “A transposon and transposase system for human application,” Molecular Therapy: The Journal of the American Society of Gene Therapy (2010) 18:674-683. [cited by applicant]
Hermans et al., “The VITAL assay: a versatile fluorometric technique for assessing CTL- and NKT-mediated cytotoxicity against multiple targets in vitro and in vivo,” J Immunol Methods (2004) 285(1):25-40. [cited by applicant]
Holler et al., “In vitro evolution of a T cell receptor with high affinity for peptide/MHC,” Proc Natl Acad Sci U S A. (2000) 97(10): 5387-5392. [cited by applicant]
Holler et al., “TCRs with high affinity for foreign pMHC show self-reactivity,” Nat Immunol. Jan. 2003;4(1):55-62. [cited by applicant]
Honegger et al., “Yet another numbering scheme for immunoglobulin variable domains: an automatic modeling and analysis tool,” J Mol Biol (2001) 309(3):657-670. [cited by applicant]
Huang et al., “DNA transposons for modification of human primary T lymphocytes,” Methods Mol Biol (2009) 506: 115-126. [cited by applicant]
Hudecek et al., “Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells,” Clin Cancer Res (2013) 19(12):3153-3164. [cited by applicant]
Hudecek et al., “The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity,” Cancer Immunol Res (2015) 3(2):125-135. [cited by applicant]
Imadome, “The clinical condition and diagnosis of EBV-T/NK-LPD (CAEBV, EBV-HLH etc.),” [Rinsho Ketsueki] Japanese J Clin Hematol (2013) 54(10):1992-98. (Reference in Japanese). [cited by applicant]
Imamoto et al., “Advantages of AlaGIn as an additive to cell culture medium: use with anti-CD20 chimeric antibody-producing POTELLIGENT™ CHO cell lines,” Cytotechnology (2013) 65:135-143. [cited by applicant]
Janeway et al., Immunobiology: The Immune System in Health and Disease, 3rd ED., Current Biology Publications (1997), p. 4:33. [cited by applicant]
Johnston, et al., “Biolistic transformation: microbes to mice,” Nature (1990) 346: 776-777. [cited by applicant]
Jores et al., “Resolution of hypervariable regions in T-cell receptor beta chains by a modified Wu-Kabat index of amino acid diversity.,” PNAS (1990) 87(23):9138-9142. [cited by applicant]
Kindt et al., “Antigens and Antibodies,” in Chapter 4 of Kuby Immunology, 6th ed., W.H. Freeman and Co., N.Y, (2007) pp. 91, 14 pages. [cited by applicant]
Klebanoff et al., “Sorting through subsets: which T-cell populations mediate highly effective adoptive immunotherapy?,” J Immunother. (2012) 35(9): 651-660. [cited by applicant]
Kochenderfer et al., “Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor,” J. Immunotherapy (2009) 32(7): 689-702. [cited by applicant]
Kochenderfer et al., “Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors,” Nature Reviews Clinical Oncology (2013) 10:267-276. [cited by applicant]
Koste et al., “T-cell receptor transfer into human T cells with ecotropic retroviral vectors,” Gene Therapy (2014) 21: 533-538. [cited by applicant]
Kotb, “Bacterial pyrogenic exotoxins as superantigens,” Clin Microbiol Rev. (1995) 8(3):411-426. [cited by applicant]
Kurucz et al., “A bacterially expressed single-chain Fv construct from the 2B4 T-cell receptor,” Proc Natl Acad Sci U S A. (1993) 90(9): 3830-3834. [cited by applicant]
Lefranc et al., “IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains,” Dev Comp Immunol (2003) 27(1):55-77. [cited by applicant]
Li et al., “Directed evolution of human T-cell receptors with picomolar affinities by phage display,” Nature Biotechnology (2005) 23:349-354. [cited by applicant]
Ling et al., “B-cell and plasma cell antigens: new and previously defined clusters,” Leucocyte typing III. (1987) 302-355. [cited by applicant]
Liu et al., “Inclusion of Strep-tag II in design of antigen receptors for T-cell immunotherapy,” Nature Biotechnology (2016) 34(4):430-434. [cited by applicant]
Lu et al., “A Rapid Cell Expansion Process for Production of Engineered Autologous CAR-T Cell Therapies,” Human Gene Therapy Methods (2016) 27(6):209-218. [cited by applicant]
Lupton et al., “Dominant positive and negative selection using a hygromycin phosphotransferase-Thymidine kinase dusion gene,” Molecular and cellular biology (1991) 11(6):3374-3378. [cited by applicant]
Maccallum et al., “Antibody-antigen interactions: contact analysis and binding site topography,” J Mol Biol (1996) 262(5):732-745. [cited by applicant]
Manuri et al., “piggyBac transposon/transposase system to generate CD19-specific T cells for the treatment of B-lineage malignancies,” Hum Gene Ther (2010) 21(4): 427-437. [cited by applicant]
Martin et al., “Modeling antibody hypervariable loops: a combined algorithm,” PNAS (1989) 86(23):9268-9272. [cited by applicant]
Mcwilliams et al., “Mutations in the 5′ end of the human immunodeficiency virus type 1 polypurine tract affect RNase H cleavage specificity and virus titer,” J Viral (2003) 77(20):11150-11157. [cited by applicant]
Methods in Molecular Medicine, vol. 58: Metastasis Research Protocols, vol. 2: Cell Behavior In Vitro and In Vivo, p. 17-25 Edited by: S. A. Brooks and U. Schumacher © Humana Press Inc., Totowa, NJ. [cited by applicant]
Miller et al., “Improved retroviral vectors for gene transfer and expression,” BioTechniques (1989) 7:980-990. [cited by applicant]
Miller et al., “Retrovirus packaging cells,” Human Gene Therapy (1990) 1:5-14. [cited by applicant]
Miyoshi et al. “Development of a self-inactivating lentivirus vector,” J Viral (1998) 72(10):8150-8157. [cited by applicant]
Naldini et al., “In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector,” Science. (Apr. 12, 1996);272(5259):263-7. [cited by applicant]
Naldini et al., “Lentiviruses as gene transfer agents for delivery to non-dividing cells”, Curr Opin Biotechnol., (Oct. 9, 1998); 5:457-63. [cited by applicant]
Park et al., “Treating cancer with genetically engineered T cells,” Trends Biotechnol. (2011) 29(11): 550-557. [cited by applicant]
Parkhurst et al., “Characterization of genetically modified T-cell receptors that recognize the CEA:691-699 peptide in the context of HLA-A2.1 on human colorectal cancer cells,” Clin Cancer Res (2009) 15:169-180. [cited by applicant]
Philpott et al., “Use of Nonintegrating Lentiviral Vectors for Gene Therapy,” Human Gene Therapy (2007) 18:483. [cited by applicant]
Portolano et al., “Lack of promiscuity in autoantigen-specific H and L chain combinations as revealed by human H and L chain “roulette”,” J Immunol (1993) 150(3):880-887. [cited by applicant]
Powell et al., “Sequence and structural determinants required for priming of plus-strand DNA synthesis by the human immunodeficiency virus type 1 polypurine tract,” J Viral (1996) 70(8):5288-5296. [cited by applicant]
Riddell et al., “The Fred Hutchinson Cancer Research Center and the University of Washington School of Medicine, Department of Medicine, Division of Oncology Oct. 7, 1991,” Human Gene Therapy (1992) 3:319-338. [cited by applicant]
Rosenberg, et al., “Cell transfer immunotherapy for metastatic solid cancer—what clinicians need to know,” Nat Rev Clin Oncol. (2011) 8(10):577-85. [cited by applicant]
Sadelain et al., “The basic principles of chimeric antigen receptor design,” Cancer Discov. (2013) 3(4): 388-398. [cited by applicant]
Scarpa et al., “Characterization of recombinant helper retroviruses from Moloney-based vectors in ecotropic and amphotropic packaging cell lines,” Virology (1991) 180:849-852. [cited by applicant]
Schlueter et al., “Specificity and Binding Properties of a Single-chain T Cell Receptor,” J Mol Biol (1996) 859-869. [cited by applicant]
Schuler et al., SYFPEITHI, Database for Searching and T-Cell Epitope Prediction. in Immunoinformatics Methods in Molecular Biology, (2007) 409(1): 75-93. [cited by applicant]
Sharma et al., “Efficient sleeping beauty DNA transposition from DNA minicircles,” Molec Ther Nucl Acids (2013) 2, e74. [cited by applicant]
Singh et al., “ProPred: prediction of HLA-DR binding sites,” Bioinformatics. (2001) 17(12): 1236-1237. [cited by applicant]
Smith et al., “Ex vivo expansion of human T cells for adoptive immunotherapy using the novel xeno-free CTS immune cell serum replacement,” Clin Transl Immunol (2015) 4:e31. [cited by applicant]
Soo Hoo et al., “Characterization of a single-chain T-cell receptor expressed in [cited by applicant]
Tai et al., “Antibody-Based Therapies in Multiple Myeloma,” Bone Marrow Research (2011) vol. 2011. Article ID 924058. [cited by applicant]
Terakura et al., “Generation of CD19-chimeric antigen receptor modified CD8+ T cells derived from virus-specific central memory T cells,” Blood (2012) 1:72-82. [cited by applicant]
Themeli et al., “Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy,” Nat Biotechnol. (2013) 31(10): 928-933. [cited by applicant]
Tsukahara et al., “CD19 target-engineered T-cells accumulate at tumor lesions in human B-cell lymphoma xenograft mouse models,” Biochem Biophys Res Commun (2013) 438(1): 84-89. [cited by applicant]
Turtle et al., “Anti-CD19 Chimeric Antigen Receptor-Modified T Cell Therapy for B Cell Non-Hodgkin Lyphoma and Chronic Lyphocytic Leukemia: Fludarabine and Cyclophosphamide Lyphodepletion Imprives In Vivo Expansion and … [cited by applicant]
Turtle et al., “Engineered T cells for anti-cancer therapy,” Curr. Opin. Immunol. (2012) 24(5): 633-39. [cited by applicant]
Van Tendeloo et al., “High-level transgene expression in primary human T lymphocytes and adult bone marrow CD34+ cells via electroporation-mediated gene delivery,” Gene Therapy (2000) 7(16): 1431-1437. [cited by applicant]
Varela-Rohena et al., “Control of HIV-1 immune escape by CD8 T cells expressing enhanced T-cell receptor,” Nature Medicine (2008) 14(12): 1390-1395. [cited by applicant]
Verhoeyen et al., “Lentiviral vector gene transfer into human T cells,” Methods Mol Biol. (2009) 506: 97-114. [cited by applicant]
Wadhwa et al., “Receptor mediated glycotargeting,” J. Drug Targeting (1995) 3: 111. [cited by applicant]
Wang et al., “Phenotypic and functional attributes of lentivirus-modified CD19-specific human CD8+ central memory T cells manufactured at clinical scale,” J Immunother. (2012) 35(9):689-701. [cited by applicant]
Wu et al., “Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook,” Cancer (2012) 18(2): 160-175. [cited by applicant]
Wulfing et al., “Correctly folded T-cell receptor fragments in the periplasm of [cited by applicant]
Zufferey et al. “Self-Inactivating Lentivirus Vector for Safe and Efficient In Vivo Gene Delivery,” J. Viral (1998) 72(12):9873-9880. [cited by applicant]
Zufferey et al., “Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo,” Nat Biotechnol. (Sep. 1997);15(9):871-875. [cited by applicant]
Aksoy et al., “Human primary T cells: A practical guide,” dated Jun. 19, 2018. Retrieved from https://peerj.com/preprints/26993.html (31 pages). [cited by applicant]
Anonymous, “Scientists helping scientists™ | WWW Optimization of Human T Cell Expansion Protocol: Effects of Early Cell Dilution,” (2018) (8 pages). [cited by applicant]
Applikon Biotechnology/BioPharma-Reporter (2016) How automation has changed the way we count cells BioPharma-Reporter.com; 1-4 (Year: 2016). [cited by applicant]
Chang et al., “Identification and selective expansion of functionally superior T cells expressing chimeric antigen receptors,” J Transl Med (2015) 13(1):161 (16 pages). [cited by applicant]
Eaker et al., “Concise review: guidance in developing commercializable autologous/patient-specific cell therapy manufacturing,” Stem Cells Transl Med. (2013) 2(11): 871-83. [cited by applicant]
Fryar et al., “Mean Body Weight, Height, Waist Circumference, and Body Mass Index Among Adults: United States, 1999-2000 Through 2015-2016,” Natl Health Stat Report. (2018) (122):1-16. [cited by applicant]
Janas et al., “Perfusion's role in maintenance of high-density T-cell cultures,” BioProcesses International. (2015) pp. 1-12. [cited by applicant]
Kahn et al., “Optimization of retroviral vector-mediated gene transfer into endothelial cells in vitro,” Circ Res. (1992) 71(6):1508-17. [cited by applicant]
Klaver et al., “T Cell Maturation Stage Prior to and During GMP Processing Informs on CAR T Cell Expansion in Patients,” Front Immunol. (2016) 7:648 (7 pages). [cited by applicant]
Lada et al., “Quantitation of integrated HIV provirus by pulsed-field gel electrophoresis and droplet digital PCR,” J Clin Microbiol (2018) 56(12):e01158 (10 pages). [cited by applicant]
Li et al., “Comparison of anti-CD3 and anti-CD28-coated beads with soluble anti-CD3 for expanding human T cells: Differing impact on CD8 T cell phenotype and responsiveness to restimulation,” J Transl Med (2010) 8(1):10… [cited by applicant]
Maude et al., “Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia,” New Engl J Med (2018) 378(5):439-448. [cited by applicant]
Neeson et al., “Ex vivo culture of chimeric antigen receptor T cells generates functional CD8+ T cells with effector and central memory-like phenotype,” Gene Therapy (2010) 17(9):1105-1116. [cited by applicant]
Okamoto et al., “A promising vector for TCR gene therapy: differential effect of siRNA, 2A peptide, and disulfide bond on the introduced TCR expression,” Mol Ther Nucl Acids (2012) 1(12):1-11. [cited by applicant]
Sun et al., “Early transduction produces highly functional chimeric antigen receptor-modified virus-specific T-cells with central memory markers: a Production Assistant for Cell Therapy (PACT) translational application,… [cited by applicant]
Tai et al., “Targeting B-cell maturation antigen in multiple myeloma,” Immunotherapy (2015) 7:1187-1199. [cited by applicant]
Turtle et al., “CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients,” J. Clin. Invest. (2016) 126(6):2123-38. [cited by applicant]
Vormittag et al., “A guide to manufacturing CAR T cell therapies,” Curr Opin in Biotechnology (2018) 53:164-181. [cited by applicant]
Wang et al., “Clinical manufacturing of CAR T cells: foundation of a promising therapy,” Molecular Therapy—Oncolytics (2016) 3:16015 (7 pages). [cited by applicant]
Xu et al., “Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15,” Blood (2014) 123(24):3750-3759. [cited by applicant]
Xu et al., “Multiparameter comparative analysis reveals differential impacts of various cytokines on CART cell phenotype and function ex vivo and in vivo,” Oncotarget (2016) 7(50):82354-82368. [cited by applicant]
Zhao et al., “Development of the First World Health Organization Lentiviral Vector Standard: Toward the production control and standardization of lentivirus-based gene therapy products,” Human Gene Therapy Methods (2017… [cited by applicant]
Akron Biotech “cGMP rHuIL-15: Exceptional purity, consistency and performance. Expand T-Cells and NK-Cells with Akron's cGMP IL-15,” (2023):1-9. [cited by applicant]
Berthois et al., “Phenol red in tissue culture media is a weak estrogen: implications concerning the study of estrogen-responsive cells in culture,” Proc Natl Acad Sci USA. (1986) 83(8):2496-500. [cited by applicant]
Dupont et al., “Comparative dose-responses of recombinant human IL-2 and IL-7 on STAT5 phosphorylation in CD4+FOXP3-cells versus regulatory T cells: a whole blood perspective,” Cytokine. (2014) 69(1):146-9. [cited by applicant]
Hinrichs et al., “Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy,” Blood. (2011) 117(3):808-14. [cited by applicant]
Life Technologies Corporation (2013) OpTmizer™ CTS™ T-cell Expansion SFM Technical information; pp. 1-2 (Year: 2013). [cited by applicant]
Marenghi et al., “The role of perfusion in maintaining high density T-cell cultures,” GE (2014):1-2. [cited by applicant]
Navarro et al., “Estrogen Stimulation Differentially Impacts Human Male and Female Antigen-Specific T Cell Anti-Tumor Function and Polyfunctionality,” Gender and the Genome. (2017) 1(4):167-179. [cited by applicant]
Okern et al., “CTS™ immune cell SR for serum free culture and expansion of human T cells,” J Immunother Cancer. (2015); 3(Suppl 2): P1. [cited by applicant]
Poltorak et al., “Expamers: a new technology to control T cell activation,” Sci Rep. (2020) 10(1):17832 (15 pages). [cited by applicant]
Qian et al., “Advances in the Development of Interleukin-2 and its Analogues,” Chinese Journal of Pharmaceuticals. (2020) 947-955. (Article in Chinese; English abstract provided). [cited by applicant]
Dong, Modern Biology, Beijing Institute of Technology Press, 1st edition, p. 328, Jul. 31, 2016 (Article in Chinese; English translation provided). [cited by applicant]
Hirakawa et al., “IL-2, IL-7, IL-15 and IL-6 Induce Differential Activation of Naive and Memory T Cell Subsets,” Blood (2015) 126(23):3425, 4 pages. [cited by applicant]
Hou et al., “Tutorial on Animal Cell Culture Techniques,” Gansu Science and Technology Press (2009) 520, Chapter 9, p. 105. (Article in Chinese; English translation provided). [cited by applicant]
Kaartinen et al., “Low interleukin-2 concentration favors generation of early memory T cells over effector phenotypes during chimeric antigen receptor T-cell expansion,” Cytotherapy (2017) 19(6):689-702. [cited by applicant]
Al-Shanti et al., “Human purified CD8+ T cells: Ex vivo expansion model to generate a maximum yield of functional cytotoxic cells,” Immunol Invest. (2007);36(1):85-104. [cited by applicant]
Bondanza et al., “IL-7 receptor expression identifies suicide gene-modified allospecific CD8+ T cells capable of self-renewal and differentiation into antileukemia effectors,” Blood. (2011) 117(24):6469-78. [cited by applicant]
Chang et al., “Investigation of interfacial properties of pure and mixed poloxamers for surfactant-mediated shear protection of mammalian cells,” Colloids Surf B Biointerfaces. (2017) 156:358-365. [cited by applicant]
Finney et al., “Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain,” J Immunol. (2004) 1… [cited by applicant]
Kemper et al., “Label-free quantitative cell division monitoring of endothelial cells by digital holographic microscopy,” J Biomed Opt. (2010) 15(3):036009 (6 pages). [cited by applicant]
Levine et al., “Global manufacturing of CAR T cell therapy” Mol. Ther. Methods & Clin. Dev. (2016) 4: 92-101. [cited by applicant]
Mak et al., “Glutathione Primes T Cell Metabolism for Inflammation,” Immunity. (2017) 46(4):675-689. [cited by applicant]
Marthandan et al., “An investigation of the effects of the antioxidants, ebselen or N-acetyl cysteine on human peripheral blood mononuclear cells and T cells,” Immun Ageing. (2013) 10(1):7 (16 pages). [cited by applicant]
Medvec et al., “Improved Expansion and In Vivo Function of Patient T Cells by a Serum-free Medium,” Mol Ther Methods Clin Dev. (2017) 8:65-74. [cited by applicant]
Amos et al., “The role of caspase 3 and BclxL in the action of interleukin 7 (IL-7): a survival factor in activated human T cells,” Cytokine. (1998) 10(9):662-8. [cited by applicant]
Jiang Bo, Fundamentals and Clinics of Apoptosis, People's Military Medical Press, p. 141, Jul. 1999 (Reference in Chinese; English translation provided). [cited by applicant]
Lada et al., “Quantitation of integrated HIV provirus by pulsed-field gel electrophoresis and droplet digital PCR,” J Clin Microbiol (2018) 56(12):e01158. [cited by applicant]
Saligrama et al., “IL-15 maintains T-cell survival via S-nitrosylation-mediated inhibition of caspase-3,” Cell Death Differ. (2014) 21(6):904-14. [cited by applicant]
Anastasov et al., “Optimized Lentiviral Transduction Protocols by Use of a Poloxamer Enhancer, Spinoculation, and scFv-Antibody Fusions to VSV-G,” Methods Mol Biol (2016) 1448:49-61. [cited by applicant]
Boyman et al., “The role of interleukin-2 in memory CD8 cell differentiation,” Adv Exp Med Biol (2010) 684:28-41. [cited by applicant]
Han et al., “Masked Chimeric Antigen Receptor for Tumor-Specific Activation,” Mol Ther (Jan. 2017) 25(1):274-284. [cited by applicant]
Krug et al., “A GMP-compliant protocol to expand and transfect cancer patient T cells with mRNA encoding a tumor-specific chimeric antigen receptor,” Cancer Immunol Immunother (2014) 63(10):999-1008. [cited by applicant]
Chatot et al., “An improved culture medium supports development of random-bred 1-cell mouse embryos in vitro,” J Reprod Fertil (Jul. 1989) 86(2):679-688. [cited by applicant]
Kueberuwa et al., “CCR7+ selected gene-modified T cells maintain a central memory phenotype and display enhanced persistence in peripheral blood in vivo,” J Immunother Cancer (Feb. 21, 2017) 5(14):1-14. [cited by applicant]
Zynda et al., “Optimization of a Phenol Red-Free T Cell Expansion Medium to Improve Performance and Workflow Flexibility,” Thermo Fisher Scientific, Poster, presented at International Society for Cellular Therapy (ISCT)… [cited by applicant]